Ebola Virus Net is the web resource for anyone interested in ebola. Ebola (Ebola hemorrhagic fever), is a severe, often fatal disease in humans and nonhuman primates such as monkeys, gorillas, and chimpanzees. Ebola is a rare and deadly disease caused by infection with a virus of the family Filoviridae, genus Ebolavirus. There are five identified Ebolavirus species, four of which have caused disease in humans. Ebola is found in several African countries. The first Ebola species was discovered in 1976 near the Ebola River in the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa. The largest outbreak to date was the epidemic in West Africa, which occurred from December 2013, to January 2016, with 28,646 cases and 11,323 deaths. Other outbreaks in Africa began in the Democratic Republic of the Congo in May 2017 and 2018. In July 2019, the World Health Organization declared the Congo Ebola outbreak a world health emergency.

When an infection does occur in humans, the virus can be spread to others through direct contact with the blood or body fluids of a person who is sick with Ebola, or through contact with objects that have been contaminated with the blood or body fluids of an infected person. Until recent, no vaccines were effective. In December 2016, Ebola was found to be 70–100% prevented by rVSV-ZEBOV vaccine, making it the first proven vaccine against the disease. More than 100,000 people have been vaccinated against Ebola as of 2019.

The objectives of Ebola Virus Net are to be the public and professional information resource for ebola and to serve as a network in the exchange of information and news related to ebola.

• Ebola virus may lurk in survivors for many years - Science
  Fri, 19 Mar 2021 07:00 GMT
• Ebola outbreak 2021- North Kivu - World Health Organization
  Wed, 17 Mar 2021 20:30 GMT
• Ebola Virus Cases Reach 23 in Guinea, Africa Through Early 2021 - Contagionlive.com
  Thu, 08 Apr 2021 16:41 GMT
• Ebola outbreak 2021- N'Zerekore, Guinea - World Health Organization
  Wed, 17 Mar 2021 14:16 GMT
• Democratic Republic of the Congo (DRC) - Ebola Situation Report #40 - April 10, 2021 - Democratic Republic of the Congo - ReliefWeb
  Sat, 10 Apr 2021 22:26 GMT
• Man's Ebola relapse spawned dozens of new cases in Africa - ABC News
  Wed, 31 Mar 2021 07:00 GMT
• Multiple Countries | Ebola Virus Disease (EVD) Outbreak: Preparedness and Response - Operations Update n° 1 (Appeal №: n° MDREBOLA21) - Guinea - ReliefWeb
  Mon, 29 Mar 2021 07:00 GMT
• Washington health officials monitoring 23 people for Ebola - KING5.com
  Thu, 25 Mar 2021 07:00 GMT
• Ebola might be a chronic infection – but here's why we shouldn't panic - The Conversation UK
  Mon, 29 Mar 2021 07:00 GMT
• Ebola Survivor May Have Started Latest Outbreak -- 5 Years Later - WebMD
  Mon, 15 Mar 2021 07:00 GMT
• The Ebola Vaccine: A Cautionary Tale - BioSpace
  Thu, 08 Apr 2021 13:11 GMT
• New Ebola outbreak kills 3 in Guinea: Africa CDC - Xinhua | English.news.cn - Xinhua
  Wed, 07 Apr 2021 01:57 GMT
• Ebola may have lingered in a survivor for 5 years before sparking new outbreak - Livescience.com
  Tue, 16 Mar 2021 07:00 GMT
• Man's Ebola Relapse Spawned 91 New Cases in Africa - Voice of America
  Thu, 01 Apr 2021 07:00 GMT
• 44 Ohioans Being Monitored for Potential Ebola Exposure - Spectrum News 1
  Mon, 22 Mar 2021 07:00 GMT

• PRO/AH/EDR> Ebola update (31): Guinea, vaccine
  Wed, 07 Apr 2021 08:34:10 -0400
  Ebola -- Guinea
  On [29 May 2020], the European Medicines Agency (EMA) human medicines committee recommended granting Zabdeno and Mvabea a positive opinion for marketing authorizations under exceptional circumstances because the applicant was able to demonstrate that it is not possible to conduct a randomized controlled study that might generate comprehensive clinical data on the efficacy of the latest Ebola vaccine even after authorization.
  This was considered acceptable in light of the ongoing Ebola

• Integration of genomic sequencing into the response to the Ebola virus outbreak in Nord Kivu, Democratic Republic of the Congo Tue, 13 Apr 2021 06:00:00 -0400
  On 1 August 2018, the Democratic Republic of the Congo (DRC) declared its tenth Ebola virus disease (EVD) outbreak. To aid the epidemiologic response, the Institut National de Recherche Biomédicale (INRB) implemented an end-to-end genomic surveillance system, including sequencing, bioinformatic analysis and dissemination of genomic epidemiologic results to frontline public health workers. We report 744 new genomes sampled between 27 July 2018 and 27 April 2020 generated by this surveillance...
• Infection Prevention and Control in Liberia 5 Years After Ebola: A Case Study Tue, 13 Apr 2021 06:00:00 -0400
  CONCLUSIONS/APPLICATION TO PRACTICE: IPC capacity in Liberia had been sustained since Ebola but was threatened by under-investments in physical resources. Donor countries should prioritize sustained support, both financial and technical, in partnership with Liberian leaders. Occupational health nurses participating in disaster response should advocate for long-term investment by donor countries in personal protective equipment, access to water, and clinician training.
• An Assessment of Anesthesia Capacity in Liberia: Opportunities for Rebuilding Post-Ebola Mon, 12 Apr 2021 06:00:00 -0400
  CONCLUSIONS: Overall, we noted several critical gaps in anesthesia and surgical capacity in Liberia, in spite of the massive global response post-Ebola directed toward health system development. Further investment across all domains is necessary to attain minimum international standards and to facilitate the provision of safe surgery and anesthesia in Liberia. The study results will be considered in development of an NSOAP for Liberia.
• Bioreactor production of rVSV-based vectors in Vero cell suspension cultures Sat, 10 Apr 2021 06:00:00 -0400
  The Vero cell line is the most used continuous cell line in viral vaccine manufacturing. This adherent cell culture platform requires the use of surfaces to support cell growth, typically roller bottles or microcarriers. We have recently compared the production of rVSV-ZEBOV on Vero cells between microcarrier and fixed-bed bioreactors. However, suspension cultures are considered superior with regard to process scalability. Therefore, we further explore the Vero suspension system for...
• Under consent: participation of people with HIV in an Ebola vaccine trial in Canada Sat, 10 Apr 2021 06:00:00 -0400
  CONCLUSIONS: Our findings support Fisher's argument of "structural coercion" in clinical trial recruitment of vulnerable individuals experiencing precarious living conditions. Clinical trials should provide more detail of the structural socio-economic conditions and healthcare needs which lie "under consent" of study participants. Going well beyond an overly convenient narrative of altruism, ethical deliberation frameworks need to sufficiently address the structural conditions of clinical...
• Health-Promoting Leadership During an Infectious Disease Outbreak: A Cross-Sectional Study of US Soldiers Deployed to Liberia Fri, 09 Apr 2021 06:00:00 -0400
  Infectious disease outbreaks are uniquely stressful for essential employees. One way to support workers is for supervisors to engage in behaviors promoting employees' well-being and attitudes toward preventive medicine practices. We examined whether health-promoting leadership contributes to these outcomes in a population of active-duty soldiers (N = 173) deployed to provide nonmedical support in Liberia during the 2014 Ebola epidemic using data reported in Sipos, Kim, Thomas, and Adler (Mil Med...
• Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV Fri, 09 Apr 2021 06:00:00 -0400
  A discovery program targeting respiratory syncytial virus (RSV) identified C-nucleoside 4 (RSV A2 EC(50) = 530 nM) as a phenotypic screening lead targeting the RSV RNA-dependent RNA polymerase (RdRp). Prodrug exploration resulted in the discovery of remdesivir (1, GS-5734) that is >30-fold more potent than 4 against RSV in HEp-2 and NHBE cells. Metabolism studies in vitro confirmed the rapid formation of the active triphosphate metabolite, 1-NTP, and in vivo studies in cynomolgus and African...
• The burden of mental disorder in Sierra Leone: a retrospective observational evaluation of programmatic data from the roll out of decentralised nurse-led mental health units Fri, 09 Apr 2021 06:00:00 -0400
  CONCLUSIONS: Nurse-led MHU can have a modest effect on the treatment gap in resource constrained environments such as Sierra Leone, particularly in epilepsy and psychosis.
• Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR Thu, 08 Apr 2021 06:00:00 -0400
  Ebola virus (EBOV) hemorrhagic fever outbreaks have been challenging to deter due to the lack of health care infrastructure in disease-endemic countries and a corresponding inability to diagnose and contain the disease at an early stage. EBOV vaccines and therapies have improved disease outcomes, but the advent of an affordable, easily accessed, mass-produced rapid diagnostic test (RDT) that matches the performance of more resource-intensive polymerase chain reaction (PCR) assays would be...
• Assessing the determinants of Ebola virus disease transmission in Baka Community of the Tropical Rainforest of Cameroon Thu, 08 Apr 2021 06:00:00 -0400
  CONCLUSION: Participants generally had poor knowledge of EVD and were at high risk of infection. We recommend rigorous sensitization campaigns in the study area to educate the population on EVD and clarify the misconceptions identified. EVD surveillance is recommended particularly as outbreaks have often been reported in the Congo Basin.